HPM Partners LLC Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)

HPM Partners LLC increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 267.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,680 shares of the biopharmaceutical company’s stock after purchasing an additional 4,861 shares during the quarter. HPM Partners LLC’s holdings in Alexion Pharmaceuticals were worth $656,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. BlackRock Inc. lifted its position in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after purchasing an additional 17,960,356 shares during the period. Vanguard Group Inc. lifted its position in Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock worth $1,754,034,000 after purchasing an additional 433,293 shares during the period. State Street Corp lifted its position in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after purchasing an additional 718,756 shares during the period. Ameriprise Financial Inc. lifted its position in Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock worth $745,579,000 after purchasing an additional 454,069 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Alexion Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after purchasing an additional 64,800 shares during the period. 94.26% of the stock is owned by hedge funds and other institutional investors.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the company’s stock in a transaction on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 2,019,734 shares of company stock valued at $235,606,846 and sold 17,070 shares valued at $2,416,869. 4.35% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “HPM Partners LLC Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://sportsperspectives.com/2017/09/10/hpm-partners-llc-raises-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several brokerages recently commented on ALXN. UBS AG reaffirmed a “buy” rating and issued a $140.00 target price (down from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. BidaskClub cut Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. J P Morgan Chase & Co raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. Evercore ISI began coverage on Alexion Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 target price for the company. Finally, Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a research report on Wednesday, August 2nd. Five equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $156.32.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 141.19 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a 50-day moving average price of $136.89 and a 200-day moving average price of $124.25. The firm has a market capitalization of $31.51 billion, a price-to-earnings ratio of 61.23 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s quarterly revenue was up 21.1% on a year-over-year basis. During the same period last year, the company earned $1.13 earnings per share. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply